Nouveau Life Pharmaceuticals Inc (NOUV)

[mick]

$NOUV share reduction ????? Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines
Nouveau Life Pharmaceuticals, Inc.
370 Amapola Ave., Suite 200-A
Torrance, CA 90501

https://www.otcmarkets.com/otcapi/company/financial-report/337833/content
_______________________________
424-358-1046
[e-mail]
2860
Quarterly Report
For the Period Ending: 03/31/2022
(the “Reporting Period”)
As of 03/31/2022, the number of shares outstanding of our Common Stock was: 6,660,963,733
As of 12/31/2021, the number of shares outstanding of our Common Stock was: 10,278,851,733
As of 12/31/2021, the number of shares outstanding of our Common Stock was: 10,278,851,733
Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and
Rule 12b-2 of the Exchange Act of 1934):
Yes: ? No: ?
Indicate by check mark whether the company’s shell status has changed since the previous reporting period:
Yes: ? No: ?
Indicate by check mark whether a Change in Control1
of the company has occurred over this reporting period:
Yes: ? No: ?
1) Name and address(es) of the issuer and its predecessors (if any)

1
“Change in Control” shall mean any events resulting in:
(i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act),
directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting
securities;
(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to
such change; or
(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting
securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent
outstanding immediately after such merger or consolidation.